Tempest Therapeutics
TPST
30 hedge funds and large institutions have $104M invested in Tempest Therapeutics in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 9 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
96% more capital invested
Capital invested by funds: $53.2M → $104M (+$51.1M)
0% more funds holding
Funds holding: 30 → 30 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.73M |
| 2 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$701K |
| 3 |
Millennium Management
New York
|
+$566K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$230K |
| 5 |
Renaissance Technologies
New York
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFCP
Twin Focus Capital Partners
Boston,
Massachusetts
|
-$515K |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
-$445K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$86.3K |
| 4 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$13K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$11.1K |
TPST Hedge Fund Activity: Q1 2019 in Review
30 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2019, worth a combined $104M — up 96% from $53.2M a quarter earlier.
Fund positioning in TPST was balanced in Q1 2019: 9 funds opened new positions, 9 closed out, 7 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.73M. The largest seller was Twin Focus Capital Partners, exiting entirely with an estimated $515K sold.
- 30 institutional investors held Tempest Therapeutics (TPST) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $104M of Tempest Therapeutics stock for Q1 2019, up 96% quarter-over-quarter.
- 9 funds opened new Tempest Therapeutics positions in Q1 2019 and 9 closed out, a net change of 0 holders.
- The largest Tempest Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $1.73M added.
- The largest Tempest Therapeutics seller in Q1 2019 was Twin Focus Capital Partners, an estimated $515K sold.
Based on aggregated 13F filings for Q1 2019.